Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. (Q42844316)
Jump to navigation
Jump to search
scientific article published on 28 October 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. |
scientific article published on 28 October 2010 |
Statements
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors (English)
Stefania Canova
Nicola Pimpinelli
Mario R Sertoli
Paola Morosini
Tania Perrone